Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 250-264-8 | CAS number: 30618-84-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
GMT is toxic if swallowed but non-toxic via dermal exposure. Inhalative toxicity was not determined because inhalation is not a relevant exposure route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05-Sep-1988 - 28-Feb-1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Iffa-Credo, Les Oncins, 69210 L'Arbresle, France
- Age at study initiation: young adults, 5 to 7 weeks old
- Weight at study initiation: males: 177-218 g, females: 150 - 186 g
- Fasting period before study: 15 - 18 h
- Housing: By sex and in groups of 5 in polycarbonate cages of type MI of internal dimensions 365 x 225 x 180 mm
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 ± 3
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- 0.104, 0.122, 0.141, 0.164, 0.192 mL/kg bw administration of test article as supplied
- Doses:
- 136, 160, 185, 210, 215, 252 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Mortality and abnormal clinical signs were noted 15 minutes after administration of the test article, then 1, 2 and 4 hours later and then daily during the 14 day study period. The animals were weighed on Day -1, Day 1 (immediately before administration of the test article), Days 8 and 15.
- Necropsy of survivors performed: yes - Statistics:
- Bliss's method and Lichfield & Wilcoxon's method used for LD50 calculation
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 172 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 153 - 193
- Remarks on result:
- other: by Bliss' method
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 181 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 162 - 201
- Remarks on result:
- other: by Lichfield & Wilcoxon's method
- Mortality:
- see table 1
- Clinical signs:
- other: - 136 mg/kg bw: Subdued behaviour was recorded in all the animals at 4 hours after treatment and prostration in one out of them on Day 2. - 160 mg/kg bw: Subdued behaviour was recorded in all the animals at 2 hours after treatment and prostration at 4 hou
- Gross pathology:
- Animals died during the study showed congested areas in the lungs and a pale aspect of the liver (at dose level of 210 mg/kg). No macroscopically noticeable abnormalities were noted when necropsying the rats killed at the end of the study (day 15).
- Interpretation of results:
- Category 3 based on GHS criteria
- Remarks:
- Migrated information
- Conclusions:
- The LD50 for GMT was 172 mg/kg calculated by Bliss' method and 181 mg/kg calculated by Lichfield and Wilcoxon's method.
Reference
LD50 calculated by Bliss' method was 172 mg/kg and 181 mg/kg calculated by Lichfield and Wilcoxon's method.
Table 1: Acute oral toxicity of GMT 75
Dose level [mg/kg] |
Sex |
# dead/ # treated |
Total Mortality [%] |
136 |
m |
0/5 |
0 |
f |
0/5 |
||
160 |
m |
2/5 |
60 |
f |
4/5 |
||
185 |
m |
2/5 |
60 |
f |
4/5 |
||
210 |
m |
2/5 |
50 |
f |
3/5 |
||
215 |
m |
4/5 |
80 |
f |
4/5 |
||
252 |
m |
4/5 |
90 |
f |
5/5 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 172 mg/kg bw
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 01-Dec-2008 - 16-Feb-2009
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 434 (Acute Dermal Toxicity - Fixed Dose Procedure)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Landesinstitut für Arbeitsschutz und Produktsicherheit
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France 53940
- Age at study initiation: Within 8 - 12 weeks
- Weight at study initiation: 192 - 209 g
- Fasting period before study: no data
- Housing: The animals were kept individually in IVC cages, type III H, polysulphone cages on Altromin saw fiber bedding
- Diet: Ad libitum
- Water: Ad libitum
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 / 12
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- % coverage: No less than 10% of the body surface was cleared for the application
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Isotonic saline
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 4
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The animals were weighed on day 0 (prior to the application) and on days 7 and 14.
- Necropsy of survivors performed: yes
- Other examinations performed: A careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes and with special attention given during the first 4 hours post-dose). As soon as the symptoms noticed they were recorded. Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- none
- Clinical signs:
- other: Signs of toxicity related to dose level used: Sighting study: Apathy, ataxia, extended hind legs, extended hind legs, tiptoeing, circular movements, abnormal posture, complete eye-closure, red tears from the eyes to the nose, and grooming were observed Ma
- Gross pathology:
- Effect on organs (related to dose level):
Sighting study: No treatment related effects were observed in any of the animals.
Main study: No treatment related effects were observed in any of the animals. - Interpretation of results:
- study cannot be used for classification
- Remarks:
- Migrated information
- Conclusions:
- The dermal LD50 was determined to be greater than 2000 mg/kg body weight. Therefore the substance is unclassified according to GHS.
Reference
Table 1: Clinical observations
Animal no./ sex |
Time of observation (post dose) |
Observations |
1 / female (sighting study) |
30 minutes |
Ataxia, extended hind legs |
1 hour |
Apathy, ataxia, circular movements, extended hind legs, tiptoeing |
|
4 h 15 min |
Apathy, ataxia, circular movements, extended hind legs, tiptoeing , red tears from the eyes to the nose |
|
23 hours |
Apathy, complete eye closure, abnormal posture (Head and breast recumbent while hind legs standing) |
|
24 hours |
Starting with grooming; (after patch removal) |
|
25 hours |
Reddish swollen eyelids |
|
day 2 |
No findings |
|
2 / female (main study) |
2 hours |
Red secretion at the nose |
4 hours |
Red secretion at the nose, abnormal posture (head and breast recumbent while hind legs standing) |
|
days 1 - 7 |
skin irritation |
|
day 8 |
Red secretion at the nose |
|
day 9 |
No findings |
|
3 / female (main study) |
2 and 4 hours |
Red secretion at the nose |
3 - 5 days |
Skin irritation |
|
day 6 |
No findings |
|
4 / female (main study) |
30 min
|
Tiptoeing, vocalisation (slightly) |
2 and 4 hours |
Red secretion at the nose, tiptoeing |
|
day l |
Abnormal posture (head and breast recumbent while hind legs standing) |
|
days 2 - 13 |
Skin irritation |
|
day 14 |
No findings |
|
5 / female (main study) |
30 min, 2 hours |
Secretion at the nose |
4 hours |
Red secretion at the nose |
|
day 1 |
Abnormal posture (head and breast recumbent while hind legs standing) |
|
days 2 - 13 |
Skin irritation |
|
day 14 |
No findings |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Justification for classification or non-classification
The available data on acute oral toxicity of the test substance meets the criteria for classification as Acute Oral Toxic Category 3 (H301) according to GHS.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.